Efficacy and safety of combination ointment "fluticasone propionate 0.005% plus mupirocin 2.0%" for the treatment of atopic dermatitis with clinical suspicion of secondary bacterial infection: An open label uncontrolled study

Indian Journal of Dermatology, Venereology and Leprology

Volumn 71, Issue 2, 2005, Pages 91-95

  Khobragade, Kunal J ^a  

^a GlaxoSmithKline Pharmaceuticals Ltd   (India)

Author keywords

Staphylococcus aureus; Superantigens; Topical antibiotic; Topical corticosteroid

Indexed keywords

ANTIINFECTIVE AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE; PSEUDOMONIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; BACTERIAL INFECTION; CHILD; CLINICAL EXAMINATION; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; FEMALE; HUMAN; INFANT; MALE; PIGMENT DISORDER; PRURITUS; RATING SCALE; SAMPLE SIZE; SCORING SYSTEM; SKIN ATROPHY; SKIN DEFECT; SKIN INFECTION; SKIN IRRITATION; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

EID: 22144474756     PISSN: 03786323     EISSN: None     Source Type: Journal    
DOI: 10.4103/0378-6323.13991     Document Type: Article

References (20)

1. Lawson V, Lewis-Jones MS, Finlay AY, Reid P, Owens RG. The family impact of childhood atopic dermatitis: The Dermatitis Family Impact Questionnaire. Br J Dermatol 1998;138:107-13.
2. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments of atopic eczema. Health Technol Assess 2000;4:1-191.
3. Hauser C, Wuethrich B, Matter L, Wilhelm JA, Sonnabend W, Schopfer K. Staphylococcus aureus skin colonization in atopic dermatitis. Dermatologica 1985;170:35-9.
4. Schlievert PM. Role of superantigens in human disease. J Infect Dis 1993;167:997-1002.
5. Akiyama H, Toi Y, Kanzaki H, Tada J, Arata J. Prevalence of producers of enterotoxins and the toxic shock syndrome toxin-1 among staphylococcus aureus strains isolated from atopic dermatitis lesions. Arch Dermatol Res 1996;288:418-20.
6. McFadden JP, Noble WC, Camp RD. Superantigenic exotoxin-secreting potential of staphylococci isolated from atopic eczematous skin. Br J Dermatol 1993;128:631-2.
7. Adachi Y, Akamatsu H, Horia T. The effect of antibiotics on the production of superantigen from staphylococcus aureus isolated from atopic dermatitis. J Dermatol Sci 2002;28:76-83.
8. Spencer CM, Wiseman LR. Topical Fluticasone Propionate: A review of its pharmacological properties and therapeutic use in the treatment of dermatologic disorders. Biodrugs 1997;4:318-34.
9. Hoare C, Li Wan Po A, Williams H. Systemic review of treatments for atopic eczema. Health Technol Assess 2000;4:1-191.
10. Hanifin JM, Tofte SJ. Update on therapy of atopic dermatitis. J Allergy Clin Immunol 1999;104:S123-5.
11. Friedlander SF, Hebert A, Allen DB; Fluticasone Pediatrics Safety Study Group. Safety of fluticasone propionate 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol 2002;46:387-93.
12. Taskapan MO, Kumar P. Role of staphylococcal superantigens in atopic dermatitis: From colonisation to inflammation. Ann Allergy Asthma Immunol 2000;84:3-12.
13. Cole GW, Silverberg NL. The adherence of staphylococcus aureus to human corneocytes. Arch Dermatol 1986;122:166-9.
14. Morishita Y, Tada J, Sato A, Toi Y, Kanzaki H, Akiyama H, et al. Possible influences of staphylococcal aureus in atopic dermatitis - the colonizing features and the effects of staphylococcal enterotoxins. Clin Exp Allergy 1999;29:1110-7.
15. Miller SJ, Aly R, Shinefeld HR, Elias PM. In vitro and in vivo antistaphylococcal activity of human stratum corneum lipids. Arch Dermatol 1988;124:209-15.
16. Lever R, Hadley K, Downey D, Mackie R. Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. Br J Dermatol 1988;119:189-98.
17. Hauk PJ, Hamid QA, Chrousos GP, Leung DY. Induction of corticosteroid insensitivity in human PBMCs by microbial superantigens. J Allergy Clin Immunol 2000;105:782-7.
18. Boguniewicz M, Sampson H, Leung SB, Harbeck R, Leung DY. Effects of cefuroxime axetil on s. aureus colonization and superantigen production in atopic dermatitis. J Allergy Clin Immunol 2001;108:651-2.
19. Ewing CI, Ashcroft C, Gibbs AC, Jones GA, Connor PJ, David TJ. Flucloxacillin in the treatment of atopic dermatitis. Br J Dermatol 1998;138:1022-9.
20. Breuer K, Haussler S, Kapp A, Werfel T. Staphylococcus aureus: Colonizing features and influence of an antibacterial treatment in adults with atopic dermatitis. Br J Dermatol 2002;147:55-61.